Member Spotlight

 

Celerion

A leader in early clinical research, Celerion provides comprehensive clinical research and bioanalytical services to pharmaceutical, biotechnology and generic organizations globally. Headquartered in Lincoln, Celerion was formed in 2010 through the acquisition of the early-stage operations of MDS Pharma Services. Through legacy companies, Celerion has had a presence in Lincoln for over 80 years, 40 of which have been focused on clinical research

Led by Chief Executive Officer Susan Thornton PhD, the company employs over 850 scientists and other staff members at seven locations globally. More than 250 employees work out of the Lincoln location.

Celerion’s laboratory in Lincoln is focused on bioanalytical services. Additionally, the Lincoln facility is one of few sites in the industry that offer both clinical study conduct and pharmacology services (including protocol and study design, data analysis, biostatistics and reporting) as well as a bioanalytical laboratory in one location.

“Because our data analysis and clinical conduct teams are at the same facility, we can easily and effectively deliver adaptive study design solutions for our clients,” said Rafiq Islam, senior director of global bioanalytical services. “The on-site bioanalytical services also enables samples to be walked to the lab, and therefore eliminates the risk, cost and time associated with shipping.”

Throughout its operations, Celerion has 650 clinical research beds, including 24 in-hospital beds that are available through the company’s alliance with Bryan Hospital and which allow researchers access to state-of-the-art equipment including MRI and PET scans as well as CT, EMG, EGD and CNS/cognitive testing capabilities.

Celerion’s focus on applied translational medicine means that the company applies its expertise and experience to translate nonclinical research to optimize the design and conduct of clinical studies and thereby help drug developers answer key questions related to efficacy, patient safety and drug-drug interaction.

Celerion looks forward to working with other Bio Nebraska members to strengthen the relationship between life sciences companies and higher education, said Islam. “Developing talent, meeting existing and future workforce needs and retaining talented college graduates are all vital to the continued growth and success of the life sciences industry in Nebraska.”

Gallery: Sidebar

FEATURED MEMBERS

titleBorder

CareerCenter graphic

CAREER CENTER
titleBorder

CelerionATM 4C SOLID2 TN

MEMBER SPOTLIGHT

titleBorder

National Bioeconomy Blueprint

2014 Bioscience Industry
Development Report

BIOSCIENCE REPORTS

titleBorder

investnebraska

FEATURED WEBSITE

titleBorder